
浏览全部资源
扫码关注微信
400016 重庆,重庆医科大学附属第一医院血液内科
[ 刘林,电话:(023)89011532,E-mail:liul7776@aliyun.com LIU Lin,Tel: 86-23-89011532,E-mail:liul7776@aliyun.com
收稿:2017-09-21,
修回:2017-11-06,
纸质出版:2018-02-15
移动端阅览
朱春霞, 王利, 罗小华, 等. 精子相关抗原6基因以非P53依赖方式促进TRAIL诱导的骨髓增生异常综合征细胞凋亡[J]. 第三军医大学学报, 2018,40(3):198-204.
Chunxia ZHU, Li WANG, Xiaohua LUO, et al. Sperm-associated antigen 6, independent on P53, regulates cell apoptosis of myelodysplastic syndromes induced by TRAIL[J]. Journal of Third Military Medical University, 2018, 40(3): 198-204.
朱春霞, 王利, 罗小华, 等. 精子相关抗原6基因以非P53依赖方式促进TRAIL诱导的骨髓增生异常综合征细胞凋亡[J]. 第三军医大学学报, 2018,40(3):198-204. DOI: 10.16016/j.1000-5404.201709167.
Chunxia ZHU, Li WANG, Xiaohua LUO, et al. Sperm-associated antigen 6, independent on P53, regulates cell apoptosis of myelodysplastic syndromes induced by TRAIL[J]. Journal of Third Military Medical University, 2018, 40(3): 198-204. DOI: 10.16016/j.1000-5404.201709167.
目的
2
研究精子相关抗原6(sperm-associated antigen 6,SPAG6)基因是否以P53依赖方式促进TRAIL诱导的骨髓增生异常综合征(myelodysplastic syndrome,MDS)细胞凋亡。
方法
2
通过P53
kd
RNA慢病毒转染人结肠癌细胞株HCT116筛选P53基因沉默的最佳靶点,利用筛选出来的最佳靶点序列转染SKM-1细胞;加入嘌呤霉素提高转染效率,RT-PCR及Western blot检验P53基因的干扰效果,构建SKM-1 P53
kd
细胞模型。用SPAG6
kd
RNA慢病毒载体转染SKM-1和SKM-1 P53
kd
细胞,RT-PCR及Western blot验证。用CCK-8法检测重组人可溶性TRAIL蛋白(rTRAIL)对SKM-1细胞的适宜作用浓度。Western blot检测rTRAIL处理后SKM-1和SKM-1 P53
kd
细胞株中Caspase-8、cleaved-PARP、PARP的表达水平。
结果
2
构建了SKM-1 P53
kd
细胞模型,转染率在90%以上,P53基因在mRNA和蛋白表达水平较对照组均显著降低(
P
<
0.01)。SPAG6
kd
RNA慢病毒载体成功感染SKM-1细胞和SKM-1 P53
kd
细胞,转染率均在80%以上,SPAG6基因表达较对照组明显降低(
P
<
0.01)。随着rTRAIL浓度的增加,细胞生长逐渐被抑制,30 ng/mL TRAIL诱导的细胞凋亡与对照组差异没有统计学意义,100 ng/mL和300 ng/mL TRAIL显著诱导SPAG6
kd
细胞凋亡(
P
<
0.05),而P53基因沉默与否并没有影响该结果,rTRAIL处理后细胞凋亡标志分子明显激活或水平升高,细胞中Caspase-8、cleaved-PARP、PARP的表达水平在SKM-1和SKM-1 P53
kd
细胞中差异无统计学意义(
P
>
0.05)。
结论
2
SPAG6基因以非P53依赖方式促进TRAIL诱导的MDS细胞凋亡。
Objective
2
To investigate the sperm-associated antigen 6 (SPAG6) regulating cell apoptosis of myelodysplastic syndromes (MDS) induced by the TRAIL whether is dependent on P53.
Methods
2
The P53-knoc
k down RNA (P53
kd
RNA) lentiviral vector was transfected into HCT116 cells to obtain the most effective shRNA-containing plasmid. To construct SKM-1 P53
kd
cells model
the most effective interference sequence was transferred into SKM-1 cells
with the transfection efficiency being increased by purinomycin. Then the interference efficiency was determined by quantitative reverse transcription PCR (RT-PCR) and Western blotting. Next
the SPAG6
kd
RNA-expressing lentiviral vector was transferred into SKM-1 cells and SKM-1 P53
kd
cells
and the interference efficiency was verified by RT-PCR and Western blotting. Cell apoptosis was measured after they were treated with recombinant human sTRAIL (rTRAIL) of different concentrations by CCK-8 assay. The expression levels of PARP
cleaved PARP and Caspase-8 were measured by Western blotting after the cells were treated with rTRAIL.
Results
2
The SKM-1 P53
kd
cell model was successfully constructed
with the transfection rate over 90%
and both RT-PCR and Western blotting indicated the significant decrease of P53 expression (
P
<
0.01). The SPAG6
kd
RNA lentiviral vector was also successfully infected the SKM-1 cells and SKM-1 P53
kd
cells
and the transfection rate was more than 80%. The expression of the SPAG6 was decreased significantly after the transfection (
P
<
0.01). With the concentration of TRAIL was increased
cell growth was inhibited gradually. When the concentration was 30 ng/mL
there was no difference in cell apoptosis between the treated cells and the control cells
but 100 and 300 ng/mL obviously induced cell apoptosis (
P
<
0.05)
and P53 knockdown showed no effect on the results. rTRAIL treatment increased the expression of apoptotic molecules and enhanced cell apoptosis
but there were no significant differences in the expression levels of PARP
cleaved PARP and Caspase-8 between the SKM-1 cells and
SKM-1 P53
kd
cells (
P
>
0.05).
Conclusion
2
SPAG6 is not depend on P53 in regulating cell apoptosis of MDS induced by TRAIL.
COGLE C R, CRAIG B M, ROLLISON D E, et al . Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries[J ] . Blood, 2011, 117(26): 7121-7125. DOI:10.1182/blood-2011-02-337964.
GANGAT N, PATNAIK M M, TEFFERI A. Myelodysplastic syndromes: contemporary review and how we treat[J]. Am J Hematol, 2016, 91(1): 76-89. DOI:10.1002/ajh.24253.
ZEIDAN A M, LINHARES Y, GORE S D. Current therapy of myelodysplastic syndromes[J]. Blood Rev, 2013, 27(5): 243-259. DOI:10.1016/j.blre.2013.07.003.
STEINBACH D, SCHRAMM A, EGGERT A, et al . Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia[J ] . Clin Cancer Res, 2006, 12(8): 2434-2441. DOI:10.1158/1078-0432.CCR-05-2552.
杨碧慧, 张玉琳, 王利, 等.SPAG6基因RNAi慢病毒载体的构建及其对SKM-1细胞凋亡的影响[J].第三军医大学学报, 2015, 37(5):474-479.DOI:10.16016/j.1000-5404. 201408199.
YANG B H, ZHANG Y L, WANG L, et al .Construction of lentiviral vector for SPAG6 RNA interference and its influence on apoptosis of SKM-1 cells[J ] . J Third Mil Med Univ, 2015, 37(5):474-479.DOI:10.16016/j.1000-5404.201408199.
YANG B, WANG L, LUO X, et al . SPAG6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis[J ] . Int J Oncol, 2015, 46(2): 649-656. DOI:10.3892/ijo.2014.2768..
LI X, YANG B, WANG L, et al . SPAG6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes[J ] . Oncol Rep, 2017, 37(5): 2839-2846. DOI:10.3892/or.2017.5540.
ZHAO J, LU Y, SHEN H M. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells[J]. Cancer Lett, 2012, 314(1): 8-23. DOI:10.1016/j.canlet.2011.09.040.
NEILSON L I, SCHNEIDER P A, VAN DEERLIN P G, et al . cDNA cloning and characterization of a human sperm antigen (SPAG6) with homology to the product of the Chlamydomonas PF16 locus[J ] . Genomics, 1999, 60(3): 272-280. DOI:10.1006/geno.1999.5914.
SAPIRO R, TARANTINO L M, VELAZQUEZ F, et al . Sperm antigen 6 is the murine homologue of the Chlamydomonas reinhardtii central apparatus protein encoded by the PF16 locus[J ] . Biol Reprod, 2000, 62(3): 511-518. DOI:10.1095/biolreprod62.3.511.
ZHANG Z, JONES B H, TANG W, et al . Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16[J ] . Mol Cell Proteomics, 2005, 4(7): 914-923. DOI:10.1074/mcp. M400177-MCP200.
SILIŅA K, ZAYAKIN P, KALNIŅA Z, et al . Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients[J ] . J Immunother, 2011, 34(1): 28-44. DOI:10.1097/CJI.0b013e3181fb64fa.
WANG L, FIDLER C, NADIG N, et al . Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays[J ] . Haematologica, 2008, 93(7): 994-1000. DOI:10.3324/haematol.12603.
BOULTWOOD J, PELLAGATTI A, CATTAN H, et al . Gene expression profiling of CD34+ cells in patients with the 5q-syndrome[J ] . BrJ Haematol, 2007, 139(4): 578-589. DOI:10.1111/j.1365-2141.2007.06833.x.
MAO Y, YAN R, LI A, et al . Lentiviral vectors mediate long-term and high efficiency transgene expression in HEK 293T cells[J ] . Int J Med Sci, 2015, 12(5):407-415.DOI:10. 7150/ijms.11270.
KRISHNAKUMAR R, KRAUS W L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets[J]. Mol Cell, 2010, 39(1): 8-24. DOI:10.1016/j.molcel.2.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621